Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 7711 results

  1. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development [GID-TA11091] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  2. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 10 January 2025.

    Technology appraisal guidance
    In consultation

  4. Obinutuzumab for treating lupus nephritis ID6420

    In development [GID-TA11478] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  6. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  7. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  8. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]

    In development [GID-TA10959] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  9. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  10. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

    NICE guideline
    In development

  11. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development [GID-TA11484] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Artificial intelligence software to help detect and characterise colorectal polyps

    In development [GID-DG10118] Expected publication date: 22 January 2026

    Diagnostics guidance
    In development

  13. Teprotumumab for treating thyroid eye disease [ID6432]

    In development [GID-TA11531] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  14. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development [GID-TA11140] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  15. Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development